SCHEMBL5742233

SCHEMBL5742233

COc1cc(CC(=O)NO)cc(OC)c1OC

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.60
LMNA P02545 4/20 0.56
SMN1; SMN2 Q16637 7/20 0.55
MAPK10 P53779 2/20 0.55
ALOX12 P18054 1/20 0.55
ALDH1A1 P00352 4/20 0.53
HTT P42858 4/20 0.53
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
GAA P10253 1/20 0.52
MAPK1 P28482 1/20 0.52
CCNT1 O60563 1/20 0.51
CCNE1 P24864 1/20 0.51
CDK2 P24941 1/20 0.51
CDK9 P50750 1/20 0.51
CDK5 Q00535 1/20 0.51
CDK5R1 Q15078 1/20 0.51
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4320604 0.86 KDM4E (0.60) KDM4ELMNASMN1; SMN2MAPK10ALOX12
SCHEMBL11415704 0.83 KMT2A (0.65) LMNASMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL14543978 0.83 SMN1; SMN2 (0.59) KDM4ELMNASMN1; SMN2MAPK10ALOX12
SCHEMBL7131019 0.81 KMT2A (0.58) KDM4ELMNASMN1; SMN2MAPK10ALOX12
SCHEMBL10744953 0.81 ALDH1A1 (0.56) KDM4ELMNASMN1; SMN2MAPK10ALOX12
SCHEMBL7046945 0.81 PTGS2 (0.57) KDM4ELMNASMN1; SMN2MAPK10ALOX12
SCHEMBL5740650 0.81 HDAC6 (0.47) KDM4ELMNASMN1; SMN2KMT2AMEN1
SCHEMBL21156696 0.81 EPHX2 (0.64) KDM4ELMNASMN1; SMN2ALDH1A1HTT
SCHEMBL5741738 0.81 KDM4E (0.51) KDM4ESMN1; SMN2ALDH1A1HTTKMT2A
SCHEMBL21101917 0.80 KDM4E (0.55) KDM4ELMNASMN1; SMN2MAPK10ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1383729-A4 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2006-04-19 EP claimed
US-20040267015-A1 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION 2004-12-30 US claimed
EP-1383729-A1 PEPTIDE DEFORMYLASE INHIBITORS SmithKline Beecham Corporation (US) 2004-01-28 EP claimed
WO-2002081426-A1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-10-17 WO claimed
EP-1383729-A4 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2006-04-19 EP disclosed
US-20040267015-A1 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION 2004-12-30 US disclosed
EP-1383729-A1 PEPTIDE DEFORMYLASE INHIBITORS SmithKline Beecham Corporation (US) 2004-01-28 EP disclosed
WO-2002081426-A1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040267015-A1 Peptide deformylase inhibitors PDF, PEPD, DPEP1 KDM4E 2373/4885LMNA 2554/4885SMN1; SMN2 2376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.